Nicotinamide for Leber's Hereditary Optic Neuropathy
Part of Brain & nervous system, Eyes & vision, Genetic & congenital, Hormones & metabolism clinical trials.
This study tests whether nicotinamide (vitamin B3) can slow or improve vision loss in people with a specific form of LHON. You may be able to join if your symptoms began recently and you have not taken certain other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years of age or older.
- You have been diagnosed with LHON caused by one of two specific genetic changes (m.11778G>A or m.3460G>A).
- Your LHON symptoms started less than 18 months ago.
- You have not taken nicotinamide for at least 3 months.
- You are not currently taking idebenone (or have not taken it in the last 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy injection into the eye to improve vision in people with a specific type of inherited optic nerve disease called Leber’s hereditary optic neuropathy (LHON). It is aimed at people who have a particular genetic change and a history of vision loss lasting long enough to measure change, while checking for safety first.
This trial tests a gene therapy called GS010 given as an injection into the eye for people with vision loss from LHON. It aims to see if it can help improve vision in both eyes.
This trial tests whether a vitamin B3 supplement called nicotinamide can help slow down vision loss in people with glaucoma. It is for those with moderate disease who are already on treatment.
This trial tests whether nicotinamide (a form of vitamin B3) can slow vision changes from open-angle glaucoma. It compares nicotinamide versus a placebo (inactive pill) in adults with early to moderate disease.
This trial studies whether nicotinamide (a form of vitamin B3/niacin) can slow or affect glaucoma progression. You may be eligible if you have newly diagnosed, untreated glaucoma or if you have treated glaucoma with measurable visual field changes.
This study uses a special eye scan (OCT) to look at the layer of nerve fibers in the retina of people who carry (or don't carry) a specific gene change linked to Leber Hereditary Optic Neuropathy (NOHL). The goal is to find early warning signs in the blood that might show who is at risk of losing vision.
Hear when a new Leber Hereditary Optic Neuropathy (LHON) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.